NuSkin Enterprises, Inc. 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Nu Skin Enterprises reported Q2 2026 revenue of approximately $320 million, with an adjusted earnings per share near the midpoint of the previously communicated range.
- Gross margin for the quarter was 68.2%, with the core Nu Skin business margin improving to 77.7%.
- Selling expenses were 33.7% of revenue, and general and administrative expenses declined by $15.9 million year over year.
- The company recorded a $78.9 million non-cash goodwill impairment charge related to its Rise manufacturing reporting unit and a $167.5 million non-cash valuation allowance on U.S. deferred tax assets.
- Operating cash flow for the quarter was $10.6 million, ending with $189.6 million in cash and cash equivalents and total debt of $213.7 million.
- Nu Skin returned $2.9 million to shareholders through dividends during the quarter and had $137.3 million remaining under its share repurchase authorization.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, B.G. Hunt, Investor Relations. Please go ahead.
Thanks, Daniel, and good afternoon, everyone. I am joined by Ryan Napierski, President and CEO, and by our Interim CFO, Chelsea Lantz. Today, we will be sharing Nu Skin's Q2 2026 results and providing guidance for the remainder of the year. Before I turn time over to Ryan, let me point out that on today's call, comments will be made that include forward-looking statements. These statements involve important risks and uncertainties, and actual results may differ materially from those discussed or anticipated. Please refer to today's earnings release and our SEC filings for a complete discussion of these risks. Also during the call, certain financial numbers may be discussed that differ from comparable numbers obtained in our financial statements. We believe these non-GAAP numbers assist in comparing period-to-period results in a more consistent manner. Please refer to our investor website, ir.nuskin.com, for any required reconciliation of these non-GAAP numbers.
With that, I would like to turn the call over to Ryan.
Thanks, B.G. Good afternoon, everyone. Thanks for joining the call. Over the past quarter, our team around the world has been focused upon aligning our top leaders around the next era of opportunity for Nu Skin as we extend our anti-aging leadership position with the introduction of our new innovation, Prysm iO. The field is now learning, adapting, and incorporating this new technology into their business models, which contributed to second quarter revenue of approximately $320 million. Our focus on profitability and operational efficiency helped us achieve adjusted earnings per share near the midpoint of our previously communicated range. We have made meaningful progress on our strategic priorities, including expanding our Prysm iO platform and global rollout, working to align and activate our sales leaders via an enhanced Leader Elite achievement and incentive roadmap, and preparing India for formal opening.
We're building capabilities that we believe will strengthen our competitive position and create sustainable growth over time as we advance our vision to becoming the world's number one leadership company, powering our intelligent anti-aging platform. As we have greater clarity and line of sight on the remainder of the year, we are updating our full-year revenue and EPS guidance, which Chelsea will cover in just a few minutes. Let me briefly update you on the three strategic priorities that continue to guide our business forward. Our first priority is extending Nu Skin's leadership position in intelligent anti-aging. For nearly two decades, ageLOC has differentiated Nu Skin through world-class anti-aging science, generating approximately $16 billion in cumulative revenue. Today, advances in epigenetics and biological aging research are creating an entirely new frontier.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring